Clonal hematopoiesis of indeterminate origin has been defined as the presence of somatic mutations in hematopoietic stem cells at a variant gene frequency of more than 2%.
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.
Long-term follow-up confirmed preliminary results suggesting that rituximab maintenance following treatment with R-CHOP is safe and effective.
Severe comorbidities were found to be associated with increased all-cause and lymphoma-specific mortality compared with patients without comorbidities.
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
